PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review

Simple item page
dc.contributor.authorBektur, C.
dc.contributor.authorNurgozhin, T.
dc.creatorC., Bektur
dc.date.accessioned2017-12-13T08:57:51Z
dc.date.available2017-12-13T08:57:51Z
dc.date.issued2014-05-01
dc.identifierDOI:10.1016/j.jval.2014.03.409
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301514004604
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2871
dc.relation.ispartofValue in Health
dc.rights.licenseCopyright © 2014 Published by Elsevier Inc.
dc.titlePCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review
dc.typeArticle
elsevier.aggregationtypeJournal
elsevier.coverdate2014-05-01
elsevier.coverdisplaydateMay 2014
elsevier.identifier.doi10.1016/j.jval.2014.03.409
elsevier.identifier.eid1-s2.0-S1098301514004604
elsevier.identifier.piiS1098-3015(14)00460-4
elsevier.issue.identifier3
elsevier.issue.nameISPOR 19th Annual International Meeting Research Abstracts
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA70
elsevier.volume17

Files

Collections

Center for Life Sciences